Novo Nordisk | NVO - Assets


Novo Nordisk reported DKK90.92B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
ANI Pharmaceuticals USD 1.49B 72.14M Jun/2026
Aurora Cannabis CAD 601.09M 174.2M Mar/2026
Bausch Health Companies USD 24.79B 296M Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Canopy Growth CAD 1.12B 12.54M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Drreddys Laboratories INR 579.35B 573.08B Mar/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Novo Nordisk DKK 90.92B 468.3B Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Phibro Animal Health USD 1.45B 39.56M Mar/2026
Prestige Brands USD 4.57B 1.07B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
Supernus Pharmaceuticals USD 1.43B 72.62M Jun/2026
Zoetis USD 15.08B 77M Jun/2026